King Andrew James's Form 4 filing
Chinook Therapeutics, Inc. (KDNY) · filed Feb 15, 2023
- Accession no.
- 0001209191-23-009766
- Filed
- Feb 15, 2023
- Trade date
- Feb 10, 2023
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $56.8K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| King Andrew JamesCIK 0001823187 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | MOption exerciseAcquired | +6,803 | –F1 | – | 21,884 | Direct | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −2,392 | $23.75 | −$56,810 | 19,492 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | MOption exerciseDisposed | −6,803 | $0.00 | $0 | 6,802 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Referenced by the price of 1 transaction in Table I.